ClinicalTrials.gg
Active, not recruitingNCT06784648Updated Oct 2, 2026

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

A Phase 1/2 interventional study of pembrolizumab (KEYTRUDA®) and BI-1607 in Melanoma Metastatic, Melanoma of Skin and Melanoma BRAF V600E/K Mutated, sponsored by BioInvent International AB. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Primary conditionUveal MelanomaRegistry: MelanomaReclassifiedWhy we changed it
Registry
Melanoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uveal Melanoma
Why
  1. The study's listed conditions name Uveal Melanoma, a narrower term within Melanoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

Updated Oct 2, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Uveal Melanoma with a site in Spain — 4 open to participants now, 11 under way, 4 of them phase 3. Uveal Melanoma · Spain.

Planned enrollment
19th of 22
35 · median 94
Started
2024
with 1 other
Phase 1/2
5 of 22
none open now
Primary completion
2026-09
later than 1 of 10 live
Registered
20th of 22
by date
Lead sponsor
1 of 22
BioInvent International AB

Among the 22 studies in Uveal Melanoma with a site in Spain, this one is the 19th largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 1 of the 10 other live ones, and was the 20th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

4 of the 22 studies in Uveal Melanoma with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Spain, or all of them as a file.
02

Study summary

Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically. Melanoma is a type of skin cancer that starts in melanocytes, the cells that make the pigment that gives skin its color. In people with cancer, the body cannot control the growth of cells, which can come together to form tumors. This trial's new treatment is called BI-1607. BI-1607 is designed to work by improving the effectiveness of other targeted therapies already used for melanoma treatment; ipilimumab and pembrolizumab. BI-1607 will improve the ability of these two treatments to help the body's defense system to destroy cancer cells.

Read the detailed description

Trial Participants: This trial will include an estimated number of 35 participants with melanoma cancer who have not been helped by standard treatments.

The main purposes of this trial are :

  1. To learn about the safety and tolerability of BI1607 when received in combination with ipilimumab and pembrolizumab,
  2. To determine the best dose (quantity) of both BI-1607 and ipilimumab when combined with pembrolizumab, and
  3. To see if this triple combination therapy of BI-1607/ipilimumab/ pembrolizumab is more effective.

To investigate this, the researchers will study:

  • what medical problems can happen during the trial, whether there are changes in the participants' health, how many participants reduce their dose of treatment or stop treatment for a period during the trial, and how many participants have medical problems that cause them to stop their trial treatment early.
  • how many participants have dose-limiting toxicities (also called "DLTs", which are medical problems severe enough to stop the trial doctors from increasing a treatment dose in the next group of participants).

    2. The researchers will also study the following additional questions in this trial:

  • how BI-1607 acts in the body when received with ipilimumab/pembrolizumab.
  • whether the triple combination at varying doses of BI-1607 and ipilimumab acts in the participants' bodies as expected and has a desired effect on certain proteins in the participants' immune systems.
  • the number of participants who produce "antibodies" against BI-1607 and tolerability. Antibodies are proteins which are part of the immune system that help fight an infection. However, the body can produce antibodies against a treatment, which can stop the treatment from working properly.
  • how many participants' tumors shrink after receiving BI-1607 in combination with ipilimumab/pembrolizumab, and how long do their tumors shrink before their melanoma get worse or they pass away.

What is planned to happen during this trial: The participants are planned to be in this trial for a maximum of 25.5 months. This trial started end of 2024 and is planned to end in 2028.

This trial will have 2 parts, called Phase 1 and Phase 2.

In Phase 1, at least 15 participants will receive BI-1607 and ipilimumab once every three weeks over four treatment time points, i.e., 12 weeks. Pembrolizumab will be added to the combination treatment at the third and fourth treatment. If the participant continues in the trial thereafter, pembrolizumab will be administered alone every third week from the fifth week onwards, up to a total of 35 treatments or approximately 2 years. This phase 1 will likely contain 4 groups of participants receiving different dose levels of treatments. After the participants in the first dose group have received their first treatments, the Sponsor, in collaboration with researchers, decides if this dose is safe, and the dose will be increased in the next group of participants.

In Phase 2, approximately 20 participants will receive BI-1607 at the selected dose that the Sponsor and researchers decide is safe during Phase 1. BI-1607 will be administered once every three weeks in combination with both ipilimumab and pembrolizumab over four treatment time points, i.e., 12 weeks. Thereafter, pembrolizumab will be administered alone every third week, up to a total of 35 treatments or approximately 2 years.

In both phases, the treatments will be administered via an "IV infusion" in which an IV line is inserted into a vein usually in the arm. The treatments will be dosed in milligrams, also called "mg". The lowest dose of BI-1607 will be 350 mg, and the highest possible dose will be 700 mg. Ipilimumab will be given to participants at a dose of 1 mg/kg body weight or 3 mg/kg. The dose of pembrolizumab will be 200 mg.

Throughout the trial, the researchers will check the participants' health and any medical problems, ask about any medications they are receiving, take blood, tumor, and urine samples, and scan their tumors. The researchers will do these tests to learn how safe BI-1607 is in combination with ipilimumab/pembrolizumab, how the drug acts in the body, and how the treatment affects the participants' tumors.

Benefits of this trial: There is no guarantee that the participants will receive any benefit from participating in this trial. However, their participation may help other people who have melanoma receive better care in the future.

Risks of this trial: Participant safety is the most important factor in clinical trials. However, it cannot be guaranteed that the participants will not have medical problems during this trial. The clinical researcher will determine if the participant should no longer take part in the study if the results show the treatment doses are not safe. The Sponsor, Ethics Committee, or Regulatory Authority may also decide to stop the study at any time for any reason.

03

Conditions studied

  • Melanoma Metastatic
  • Melanoma of Skin
  • Melanoma BRAF V600E/K Mutated
  • Melanoma Recurrent
  • Melanoma Stage III or IV
  • Melanoma
  • Melanoma Negative for bRAF
  • Melanoma Negative for nRAS
  • Melanomas
  • Uveal Melanoma, Metastatic

Browse trials for

Keywords

  • anti-CTLA-4
  • anti-PD-1
  • resistant anti-PD-1
  • progressed on treatment with an anti-PD-1/L1
  • metastatic
04

In context

Uveal Melanoma Reclassified

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

This study's planned enrollment of 35 is close to the median of 37 across 222 interventional studies indexed under Uveal Melanoma.

Browse Uveal Melanoma studies →

Lead sponsor

BioInvent International AB is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Compared within Uveal Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Melanoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is willing and able to provide written for the trial.
  2. Is ≥ 18 years of age on the day of signing informed consent.
  3. Has confirmed advanced melanoma (unresectable or melanoma) with established disease progression.
  4. Participants must have progressed on treatment with an /L1 mAb. Subjects with uveal melanoma are not required to have received any prior anti-PD-1/L1 treatment. PD-1 treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of an approved anti-PD-1/L1 mAb.
    2. Has demonstrated disease progression after anti PD-1/L1 as defined by v1.1.

      The initial evidence of disease progression is to be confirmed by a second assessment no less than four weeks from the date of the first documented disease progression, in the absence of rapid clinical progression.

    3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-1/L1 mAb.
  5. Participants may have received previous treatment with BRAF inhibitors alone or in combination with mitogen extracellular kinase (MEK) inhibitors.
  6. Has at least 1 lesion as defined by RECIST v1.1 criteria.
  7. Must be willing to provide tumour as specified in the schedule of assessments (SoA) unless otherwise discussed and agreed with the Sponsor in case a biopsy cannot be taken for a medical/safety reason.
  8. Has a of ≥ 12 weeks.
  9. Has an (ECOG) performance status of 0 or 1.
  10. Has adequate organ function as confirmed by laboratory values
  11. Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrolment.
  12. Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Has previously been treated with an mAb or anti-LAG3 mAb (anti-Lymphocyte Activation Gene 3).
  2. Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
  3. Has received the following:

    1. Chemotherapy or small molecule products within 4 weeks of first dose of BI-1607.
    2. Radiotherapy within 2 weeks of first dose of BI-1607, or has radiation-related toxicities, requiring . Participants who have previously had radiation pneumonitis are not allowed.
    3. Immunotherapy or biological anti-cancer therapy or an agent or an investigational device within 4 weeks prior to the first dose of BI-1607.
  4. Has not recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline.
  5. Has had major surgery from which the participant has not yet recovered or is scheduled to have major surgery \< 28 days prior to the first dose of trial intervention.
  6. Has received a live or within 30 days prior to the first dose of trial intervention.
  7. Is participating or planning to participate in another interventional clinical trial or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to first dose of trial intervention.
  8. Has history of allogeneic tissue/solid organ transplant.
  9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of trial intervention .
  10. Has a known additional that is progressing or has required active treatment within the past 3 years.
  11. Has known active and/or carcinomatous meningitis.
  12. Has severe to (≥ Grade 3) to pembrolizumab and/or any of its . Has known or suspected hypersensitivity to BI-1607, ipilimumab or any of their excipients. Previous isolated infusion related reactions (IRRs) are not to be considered a reason for exclusion unless Grade 4 in severity.
  13. Has an active disease that has required systemic treatment in past 2 years.
  14. Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  15. Is at high medical risk because of non-malignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals.
  16. Has a known history of (HIV) infection. No HIV testing is required unless mandated by local health authority.
  17. Has cardiac or renal amyloid light-chain amyloidosis.
  18. Is a female participant and has the possibility to become pregnant (or already pregnant or lactating/breastfeeding). However, those female participants who have a negative serum or urine pregnancy test before enrolment and agree to use a highly effective method of for 4 weeks before entering the trial, during the trial, and for 12 months after last dose of BI-1607 OR 4 months after the last dose of pembrolizumab, whichever is later are considered eligible.
  19. Is a male participant with partner(s) of (unless he agrees to use a barrier method of contraception with the female partner(s) who are using one highly effective method of contraception during the trial and for 12 months after completing treatment).
  20. Has uncontrolled or significant cardiovascular disease
  21. Has a history or there is current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or in the opinion of the treating Investigator is not in the best interest of the participant to participate.
  22. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Combination of BI-1607, Ipilimumab and pembrolizumab

    In each cohort in phase Ib BI-1607 will be given with ipilimumab in 3-week cycles for 4 cycles in combination with pembrolizumab (KEYTRUDA) from cycle 3 for up to 2 years from start of treatment. In the phase 2 pembrolizumab (KEYTRUDA) will be given in combination with BI-1607 and ipilimumab in 3-week cycles for 4 cycles then a pembrolizumab (KEYTRUDA) monotherapy will be provided from cycle 5 for up to 2 years from start of treatment.

    Biological: pembrolizumab (KEYTRUDA®) · Biological: BI-1607 · Biological: Ipilimumab (YervoyTM, 50 mg/10 mL solution)

Interventions

07

What researchers measure

Primary outcomes

  1. Safety and tolerability

    The frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  2. Safety and tolerability

    The frequency of dose interruptions, dose modifications and trial intervention discontinuations will be evaluated.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  3. Safety and tolerability

    Changes of body temperature following the infusions will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  4. Safety and tolerability

    ECG will be performed and the QTc will be used to assess the cardiac safety.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  5. Safety and tolerability

    Changes in concentrations of hematology laboratory parameters (platlet count, red blood cells count, white blood cells count) will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  6. Safety and tolerability

    Changes in blood pressure following the infusions will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  7. Safety and tolerability

    Changes in respiration rate following the infusions will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  8. Safety and tolerability

    Changes in pulse rate following the infusions will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  9. Recommended doses for the expansion cohort

    During phase 1b, to determine the recommended doses for expansion of BI-1607 and ipilimumab in combination with pembrolizumab.

    Time frame: End of Cycle 3 (each cycle is 21 days)

  10. Efficacy

    Phase 2a: The best tumour response rate (according to Response Evaluation Criteria in Solid Tumour (RECIST) v.1.1 and immune RECIST (iRECIST)) will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  11. Efficacy

    Phase 2a: The objective response rate (according to Response Evaluation Criteria in Solid Tumour (RECIST) v.1.1 and immune RECIST (iRECIST)) will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  12. Efficacy

    Phase 2a: The progression-free survival (PFS) measured in months will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  13. Efficacy

    Phase 2a: The time to response measured in months will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  14. Efficacy

    Phase 2a: The duration of response (DoR) measured in months will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  15. Efficacy

    Phase 2a: The overall survival (OS) measured in months will be used to assess the efficacy.

    Time frame: Through study completion, a maximum of 2 years

  16. Safety and tolerability

    Changes in concentrations of clinical chemistry concentrations in blood (haemoglobin, creatinin, albumin, blood urea nitrogen, potassium, sodium, calcium, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, total proteins and phosphate) will be assessed.

    Time frame: end of Cycle 4 (each cycle is 21 days)

Secondary outcomes

  1. Pharmacokinetics profile of BI-1607

    The PK parameters assessed will include area under the concentration time curve (AUC).

    Time frame: end of Cycle 4 (each cycle is 21 days)

  2. Pharmacokinetics profile of BI-1607

    The PK parameters assessed will include the maximum concentration (Cmax).

    Time frame: end of Cycle 4 (each cycle is 21 days)

  3. Pharmacokinetics profile of BI-1607

    The PK parameters assessed will include the area under the plasma concentration versus time curve (AUC).

    Time frame: end of Cycle 4 (each cycle is 21 days)

  4. Pharmacokinetics profile of BI-1607

    The PK parameters assessed will include the terminal half-life (t1/2).

    Time frame: end of Cycle 4 (each cycle is 21 days)

  5. Immunogenicity of BI-1607 when administered in combination with ipilimumab and pembrolizumab

    To assess the incidence and titre of antidrug antibodies to BI-1607 in blood serum

    Time frame: end of Cycle 4 (each cycle is 21 days)

Other outcomes

  1. Expression levels of Fc receptors, and other immunological and melanoma disease markers

    To investigate the mRNA expression levels of Fc receptors, including FcγRIIB (protein and/or nucleic acids) and other immunological and melanoma disease markers (e.g., PD-1, LDH), and to study a potential correlation of levels of expression with clinical responses.

    Time frame: end of Cycle 4 (each cycle is 21 days)

  2. Genetic background of participants with respect to FcgR

    To investigate the genetic variants of participants with respect to FcgR isoforms and explore a potential correlation of the genetic background with clinical responses.

    Time frame: First day of treatment

08

Study locations

4 sites
09

References and documents

Individual participant data

Plan to share: Yes — All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.

Supporting information: Study protocol, Clinical study report

Time frame: 1 year after the last patient last visit.

Access criteria: Abbreviated CSR published online

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in Sep 2026, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2025 → Sep 2026 and completion Dec 2025 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Jan 20, 2025
StartActual
Dec 11, 2024
Primary completionActual
Sep 9, 2026was Dec 2025
CompletionEst.
Jul 30, 2027was Dec 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites removed
Show 5 removed
  • Charité - Universitatsmedizin Berlin · Berlin, Germany
  • University Hospital Essen · Essen, Germany
  • University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ) · Mannheim, Germany
  • Velindre Cancer Centre · Cardiff, United Kingdom
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Oct 2, 2026
Primary completion
Dec 30, 2025→Sep 9, 2026 (actual)
Oct 2, 2026
Study completion
Dec 30, 2025→Jul 30, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    5 sites removed
    Show 5 removed
    • Charité - Universitatsmedizin Berlin · Berlin, Germany
    • University Hospital Essen · Essen, Germany
    • University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ) · Mannheim, Germany
    • Velindre Cancer Centre · Cardiff, United Kingdom
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    Primary completion Dec 30, 2025→Sep 9, 2026 (now actual)
    Study completion Dec 30, 2025→Jul 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06784648
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Dec 11, 2024
Primary completion
Sep 9, 2026
Completion
Jul 30, 2027 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CNTN4 Monoclonal Antibody GENA-104A16

Start the discussion